Income statement
EUR
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 15M | 19M | 7M | 4M | 1M |
| Gross Profit | 13M | 19M | 7M | 4M | 1M |
| Operating Income | -42M | -30M | -32M | -65M | -57M |
| EBITDA | -40M | -24M | -24M | -56M | -55M |
| Net Income | -41M | -28M | -28M | -64M | -61M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$1.89
+13.17% today
1Y Change
-24.62%
Window
Jun 23, 2025 → Jun 9, 2026
Coverage: 242 bars · Jun 23, 2025 → Jun 9, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
ProQR Therapeutics N.V. (PRQR) is a Healthcare stock with a market cap of $140.00M and listed on NASDAQ. The stock last traded around $1.89 and down 24.6% across the available one-year price window (Jun 23, 2025 → Jun 9, 2026). Baseline metrics include revenue growth of -19.2%, EPS growth of -11.8%, a dividend yield of 0.0%. What stands out right now is revenue -19.2%, EPS -11.8%, free cash flow -36.7% with operating margin -273.0% and ROIC -51.2%. Valuation already assumes a fairly strong business story at price/sales 8.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PRQR price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PRQR
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PRQR Max Drawdown
-55.08%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PRQR and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.3M
-62.9% YoY
FY Net Income
-$60.7M
+5.7% YoY
Free Cash Flow
-$26.5M
+61.7% YoY
Revenue Growth
-19.2%
EPS Growth
-11.8%
Gross Margin
95.8%
Net Margin
-264.9%
Income statement
EUR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 15M | 19M | 7M | 4M | 1M |
| Gross Profit | 13M | 19M | 7M | 4M | 1M |
| Operating Income | -42M | -30M | -32M | -65M | -57M |
| EBITDA | -40M | -24M | -24M | -56M | -55M |
| Net Income | -41M | -28M | -28M | -64M | -61M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
EUR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 92M | 149M | 131M | 95M | 188M |
| Total Assets | 113M | 168M | 152M | 171M | 210M |
| Total Liabilities | 63M | 79M | 107M | 105M | 96M |
| Shareholder Equity | 49M | 89M | 46M | 67M | 114M |
| Total Debt | 14M | 17M | 22M | 22M | 60M |
| Net Debt | -78M | -132M | -110M | -73M | -127M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
26M
+62.0% YoY
Capital Expenditures
484K
+31.6% YoY
Free Cash Flow
26M
+61.7% YoY
Key ratios
Gross Margin
95.8%
Operating Margin
-273.0%
Net Margin
-264.9%
ROE
-65.1%
Debt / Equity
0.28x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.